February 3, 2022

Shining Light on the Commercial Potential of Optogenetic Therapies

In a guest column at clinicalleader.com, the authors discuss the past and exciting future prospects of optogenetic therapies. Companies like GenSight, Nanoscope Therapeutics, and more are compared side by side in their "race" to get their optogenetic treatment FDA approved.

What this means for Usher syndrome: Recognizing the importance of past limitations with retinal treatments allows scientists to learn and create future therapies that are better.

Link to original article

Disclaimer: The information contained on the Usher Syndrome Coalition website and other online properties is provided for your information only. The Coalition is neither a medical service nor a scientific organization. It provides information concerning the various types of Usher syndrome that includes information developed or derived from unrelated third parties over which the Coalition has no involvement or control. The Usher Syndrome Coalition does not independently, nor in conjunction with others, attest to, deny, or comment upon the merits of the accuracy of the information provided by unrelated third parties. No reliance on medical or scientific information contained on this website should be taken by any person. You should always consult with and be guided by your Physician’s advice when considering treatment based on research results.